21868-77-9

Upstream product

• 578-66-5 8-amino quinoline 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Downstream Products

• 16082-64-7 CU-242 
• 21868-80-4 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide 
• 1394081-89-0 N-[2-(Quinolin-8-ylsulfamoyl)-phenyl]-isobutyramide 

Relevant academic research and scientific papers

NEUROPROTECTIVE QUINOLINE SULFONAMIDES

Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects w

Synthesis, in?vitro β-glucuronidase inhibitory potential and molecular docking studies of quinolines

In this study synthesis and β-glucuronidase inhibitory potential of 3/5/8 sulfonamide and 8-sulfonate derivatives of quinoline (1–40) are discussed. Studies reveal that all the synthetic compounds were found to have good inhibitory activity against β-gluc

Regioselective Access to Sultam Motifs through Cobalt-Catalyzed Annulation of Aryl Sulfonamides and Alkynes using an 8-Aminoquinoline Directing Group

The use of cobalt as catalyst in direct C-H activation protocols as a replacement for more expensive second row transition metals is currently attracting significant attention. Herein we disclose a facile cobalt-catalyzed C-H functionalization route towards sultam motifs through annulation of easily prepared aryl sulfonamides and alkynes using 8-aminoquinoline as a directing group. The reaction shows broad substrate scope with products obtained in a highly regioselective manner in good to excellent isolated yields. Mechanistic insights suggest the formation of a Co(III)-aryl key species via a rate-determining arene C-H activation during the annulation reaction.

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Sulfonamidoquinoline/palladium(II)-dimer complex as a catalyst precursor for palladium-catalyzed γ-Selective and stereospecific allyl-aryl coupling reaction between allylic acetates and arylboronic acids

On neutral territory: A neutral palladium(II)-dimer catalyst system incorporating anionic sulfonamidoquinoline ligands is effective for the γ-selective and stereospecific allyl-aryl coupling between acyclic (E)-allylic acetates and arylboronic acids. Copy

COMPOUNDS THAT INHIBIT NFκB ACTIVITY

The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment o

Convenient preparation of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors

An efficient synthesis of a series of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors was described via diazotization-induced cyclization of easily accessible N-8-quinolinyl-2-aminobenzenesulfonamides.

Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation

We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NFκB pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in bot